News
Data from the EMBARK trial suggest patients may have functional improvements taking the gene therapy between 8 and 9 years old.
10h
Pharmaceutical Technology on MSNNewborn screening strategy needs modernising as HHS disbands advisory committeeAfter sweeping cuts to US federal health agencies, the elimination of a committee responsible for recommending newborn ...
Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...
Groundbreaking gene therapy offers hope for a boy with fatal muscular dystrophy, potentially slowing disease progression and ...
And for now, Logan and his family are reeling in the moments, one fish at a time.
Quince Therapeutics advances Ataxia-Telangiectasia treatment with innovative AIDE platform, insider support, and NEAT Phase 3 ...
5d
Irish Examiner on MSNParents plead for approval of 'vital drug' to slow down their son's muscular dystrophyParents of seven-year-old boy are calling for a drug which improves muscle repair to be made available here as it is in some ...
Chronic illness affects 40 percent of school-aged children. Learn how caregivers can help reduce the stress and depression ...
A Tucson preschool teacher spotted a developmental quirk in a little boy who was then able to get early treatment for ...
Some see the shuttering of the Advisory Committee on Heritable Disorders in Newborns and Children as an opportunity for ...
The children are American citizens. As a result, the 4-year-old is now “without access to medication or contact with doctors,” USA Today reported. Those two American children aren’t the only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results